

Co-organized with *Associació Catalana per a la Recerca Oncològica i les seves implicacions Sanitàries i Socials:*



Sponsors:



Con el Aval Científico de:



Sociedad Española
de Oncología Médica

SEOM® es una marca registrada.
El aval de SEOM no implica la
organización ni financiación del evento



Young Catalan Esophago-Gastric Connection (YCEGC) 2023

Coordinators and Sites:

Dr. Carles Pericay, Hospital Mútua de Terrassa, Terrassa

Dra. Laura Visa, Hospital del Mar, Barcelona

Dra. Tamara Sauri, Hospital Clinic, Barcelona

Dra. Cinta Hierro, ICO-Badalona, Badalona



Registrations via email to: MIMALLAFRE@clinic.cat

YOUNG CATALAN ESOPHAGO-GASTRIC CONNECTION (YCEGC) 2023

Session 1	Session 2	Session 3	Session 4
28/SEP/2023	16/OCT/2023	16/NOV/2023	18/DES/2023
Localized and locally Advanced Disease	Therapies in HER2+ EG Cancers	Immunotherapy in Advanced Disease	MSI and other Therapeutic Targets
Coordinator: Dr. Carles Pericay	Coordinator: Dr. Laura Visa	Coordinator: Dr. Tamara Sauri	Coordinator: Dr. Cinta Hierro
Site: Hospital Mútua Terrassa	Site: Hospital del Mar	Site: Hospital Clinic Barcelona	Site: ICO-Badalona
 MútuaTerrassa ASSISTENCIAL	 Hospital del Mar Barcelona	 CLÍNIC BARCELONA Hospital Universitari	 ICO Institut Català d'Oncologia

Registrations via email to: MIMALLAFRE@clinic.cat

YCEGC2023_28SEP2023 S1. Localized and Locally Advanced Disease

Assembly Hall, Teaching Building, Sant Antoni Street

17:30-17:35. Welcome (Dr. Carles Pericay; Hospital Universitari Mútua Terrassa-Terrassa)

17:35-18:20. Scientific lessons

- 17:35-17:55. EGJ adenocarcinoma: perioperative chemotherapy or chemo+radiotherapy (Dra. Helena Verdaguer; H. Granollers)
- 17:55-18:15. Incorporation of immunotherapy in locally advanced disease (Dra. Belen Ruiz; H. Joan XXIII Tarragona)
- 18:15-18:20. Discussion

18:20-18:30. Coffee break

18:30-19:20. Interactive clinical cases

- How to choose the best sequence in resectable gastro-esophageal cancers: review of two illustrative cases (Dra. Kristel Quiñones; H. Mútua Terrassa)

19:20-19:30. Take home messages (Dr. Carles Pericay; Hospital Universitari Mútua Terrassa-Terrassa)

19:30-20:00. Networking activity (possibility of discussion of external cases)

YCEGC2023_16OCT2023 S2. Therapies in HER2-positive EG Cancers

PRBB Rita Levy room

17:30-17:35. Welcome (Dra. Laura Visa; Hospital del Mar)

17:35-18:20. Scientific lessons

- 17:35-17:55. Rational for antiHER2 therapy in first line for EGJ cancers (Dra. Òlbia Serra; Fundació Althaia, Manresa)
- 17:55-18:15. Treatment beyond trastuzumab in second line (Dra. Lina Candia; Hospital Clinic Barcelona)
- 18:15-18:20. Discussion

18:20-18:30. Coffee break

18:30-19:20. Interactive clinical cases

- How to choose the best therapy in HER2-positive gastro-esophageal cancers: review of two illustrative cases (Dra. Adriana Gómez; Hospital del Mar)

19:20-19:30. Take home messages (Dra. Laura Visa; Hospital del Mar)

19:30-20:00. Networking activity (possibility of discussion of external cases)

YCEGC2023_16NOV2023 S3. Immunotherapy in Advanced Disease

TBD location

17:30-17:35. Welcome (Dra. Tamara Sauri; Hospital Clínic)

17:35-18:20. Scientific lessons

- 17:35-17:55. Immune Checkpoint inhibitors in gastric cancer and therapeutic implications (Dr Félix Muñoz; Hospital St Joan Reus)
- 17:55-18:15. New standard treatment with checkpoint inhibitors in esophageal tumors (Dra. Lucia Notario; ICO-Badalona)
- 18:15-18:20. Discussion

18:20-18:30. Coffee break

18:30-19:20. Interactive clinical cases

- How to guide immunotherapy in gastro-esophageal cancers: review of two illustrative cases (Dr. Javier Muñoz; Hospital Clínic)

19:20-19:30. Take home messages (Dra. Tamara Saurí; Hospital Clínic)

19:30-20:00. Networking activity (possibility of discussion of external cases)

YCEGC2023_18DEC2023 S4. MSI and other therapeutic targets

TBD location

17:30-17:35. Welcome (Dra. Cinta Hierro; ICO-Badalona)

17:35-18:20. Scientific lessons

- 17:35-17:55. Molecular biology of MSI gastro-esophageal tumors and therapeutic implications (Dra. Laura Puntí; H.Mataró)
- 17:55-18:15. Precision medicine in gastro-esophageal tumors beyond HER2 and MSI (Dra. Maria Nieva; H.del Mar)
- 18:15-18:20. Discussion

18:20-18:30. Coffee break

18:30-19:20. Interactive clinical cases

- How to choose the best driver in gastro-esophageal cancers: review of two illustrative cases (Dra. Marta Sant; ICO-Badalona)

19:20-19:30. Take home messages (Dra. Cinta Hierro; ICO-Badalona)

19:30-20:00. Networking activity (possibility of discussion of external cases)